Kura Oncology's (KURA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Kura Oncology (NASDAQ:KURA - Free Report) in a research note issued to investors on Thursday morning,Benzinga reports. The firm currently has a $40.00 target price on the stock. HC Wainwright also issued estimates for Kura Oncology's Q1 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.76) EPS and Q4 2025 earnings at ($0.78) EPS.

A number of other equities analysts have also recently commented on KURA. Scotiabank lowered their price target on Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a report on Wednesday, January 8th. Jefferies Financial Group cut their target price on shares of Kura Oncology from $32.00 to $28.00 and set a "buy" rating on the stock in a research report on Thursday, November 21st. TD Cowen reiterated a "buy" rating on shares of Kura Oncology in a report on Thursday, November 21st. JMP Securities reissued a "market outperform" rating and set a $28.00 price objective on shares of Kura Oncology in a report on Thursday, February 6th. Finally, StockNews.com downgraded Kura Oncology from a "hold" rating to a "sell" rating in a research report on Wednesday, November 20th. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Kura Oncology currently has an average rating of "Moderate Buy" and a consensus price target of $27.13.

Remove Ads

Kura Oncology Price Performance

Shares of NASDAQ KURA traded down $0.46 during mid-day trading on Thursday, reaching $7.25. The company had a trading volume of 1,403,702 shares, compared to its average volume of 1,613,099. The firm has a market cap of $563.79 million, a price-to-earnings ratio of -3.07 and a beta of 0.78. The business's 50-day simple moving average is $8.14 and its 200 day simple moving average is $13.73. Kura Oncology has a one year low of $6.98 and a one year high of $24.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. On average, research analysts predict that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares of the company's stock, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the business's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares of the company's stock, valued at $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,729 shares of company stock valued at $92,307. 5.50% of the stock is currently owned by insiders.

Institutional Trading of Kura Oncology

Several hedge funds have recently bought and sold shares of KURA. Suvretta Capital Management LLC increased its position in shares of Kura Oncology by 8.2% during the third quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company's stock worth $149,535,000 after acquiring an additional 583,155 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Kura Oncology by 14.6% in the fourth quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company's stock valued at $41,973,000 after purchasing an additional 615,211 shares during the last quarter. RA Capital Management L.P. bought a new position in shares of Kura Oncology in the fourth quarter valued at approximately $38,769,000. Millennium Management LLC grew its stake in Kura Oncology by 180.1% in the 4th quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock valued at $20,618,000 after purchasing an additional 1,521,954 shares during the period. Finally, Geode Capital Management LLC grew its position in Kura Oncology by 2.4% during the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company's stock valued at $34,798,000 after buying an additional 41,535 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.